Overview

Corporate Presentation

Corporate Presentation - July 2022

Download Presentation

Email Alerts

Register to receive real time alerts

Sign Up

IR Contacts

Get in touch with our IR team

Contact Us

Latest Press Releases
Aug 11, 2022

Reported positive results from the Phase 2b/3 PRISM trial of Haduvio™ in the treatment of Prurigo Nodularis Completed a $55 million private placement Data from the full set of subjects in the...

Aug 9, 2022

Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis...

Aug 4, 2022

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and...

View All Press Releases

Events
Thursday, August 11, 2022
4:30pm - 5:30pm EDT

View All Events

We are developing the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems.

Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options.

Explore Our Pipeline